X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ACTAVIS (US) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ACTAVIS
EQUITY SHARE DATA
    CIPLA
Mar-18
ACTAVIS
Dec-14
CIPLA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs66319,612-   
Low Rs47911,962-   
Sales per share (Unadj.) Rs189.03,531.5-  
Earnings per share (Unadj.) Rs17.6-440.7-  
Cash flow per share (Unadj.) Rs34.0324.0-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs176.77,659.7-  
Shares outstanding (eoy) m805.12265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.5 67.6%   
Avg P/E ratio x32.5-35.8 -90.6%  
P/CF ratio (eoy) x16.848.7 34.4%  
Price / Book Value ratio x3.22.1 156.8%  
Dividend payout %17.10-   
Avg Mkt Cap Rs m459,7244,197,775 11.0%   
No. of employees `00023.621.6 109.3%   
Total wages/salary Rs m26,9010-   
Avg. sales/employee Rs Th6,446.143,473.5 14.8%   
Avg. wages/employee Rs Th1,139.40-   
Avg. net profit/employee Rs Th600.0-5,425.0 -11.1%   
INCOME DATA
Net Sales Rs m152,193939,027 16.2%  
Other income Rs m3,577-2,344 -152.6%   
Total revenues Rs m155,769936,684 16.6%   
Gross profit Rs m28,264120,631 23.4%  
Depreciation Rs m13,228203,334 6.5%   
Interest Rs m1,14229,619 3.9%   
Profit before tax Rs m17,470-114,665 -15.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775-8,411 9.2%   
Tax Rs m2,501-5,895 -42.4%   
Profit after tax Rs m14,166-117,181 -12.1%  
Gross profit margin %18.612.8 144.6%  
Effective tax rate %14.35.1 278.5%   
Net profit margin %9.3-12.5 -74.6%  
BALANCE SHEET DATA
Current assets Rs m108,141494,747 21.9%   
Current liabilities Rs m38,322360,816 10.6%   
Net working cap to sales %45.914.3 321.6%  
Current ratio x2.81.4 205.8%  
Inventory Days Days9758 167.2%  
Debtors Days Days7466 112.3%  
Net fixed assets Rs m109,411114,665 95.4%   
Share capital Rs m1,6100-   
"Free" reserves Rs m140,6820-   
Net worth Rs m142,2922,036,716 7.0%   
Long term debt Rs m36,6211,067,279 3.4%   
Total assets Rs m228,6063,732,629 6.1%  
Interest coverage x16.3-2.9 -567.5%   
Debt to equity ratio x0.30.5 49.1%  
Sales to assets ratio x0.70.3 264.6%   
Return on assets %6.7-2.3 -285.5%  
Return on equity %10.0-5.8 -173.0%  
Return on capital %10.0-3.0 -330.6%  
Exports to sales %32.80-   
Imports to sales %00-   
Net fx Rs m30,6580-   
CASH FLOW
From Operations Rs m14,628161,249 9.1%  
From Investments Rs m-8,540-386,092 2.2%  
From Financial Activity Rs m-3,855216,928 -1.8%  
Net Cashflow Rs m2,431-7,915 -30.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare CIPLA With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  CADILA HEALTHCARE  JUBILANT LIFE SCIENCES  STRIDES PHARMA SCIENCE  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS